NYSE:NNVC NanoViricides (NNVC) Stock Forecast, Price & News $1.44 +0.04 (+2.86%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.37▼$1.4650-Day Range$1.25▼$1.7052-Week Range$1.04▼$2.00Volume29,686 shsAverage Volume59,118 shsMarket Capitalization$16.75 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media About NanoViricides (NYSE:NNVC) StockNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.Read More NNVC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comNanoViricides (NYSE:NNVC) Now Covered by StockNews.comSeptember 5, 2023 | finance.yahoo.comNNVC: NanoViricides Begins Clinical Trial of NV-CoV-2September 27, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 31, 2023 | finance.yahoo.comNanoViricides progressing well with new Covid studyAugust 29, 2023 | msn.com$NNVC Reports Their Broad-Spectrum Antiviral Drugs Human Clinical Trial Is Progressing SuccessfullyAugust 23, 2023 | proactiveinvestors.comNanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against virusesAugust 21, 2023 | finance.yahoo.comThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricidesJuly 18, 2023 | benzinga.comSARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?September 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 13, 2023 | finance.yahoo.comNanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research AnalystJuly 11, 2023 | marketwatch.comNanoViricides Shares Surge on NV-387 Showing in RSV >NNVCJuly 11, 2023 | benzinga.comWhy Are NanoViricides Shares Gaining TodayJuly 11, 2023 | finance.yahoo.comCompany’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricidesJuly 10, 2023 | benzinga.comNovel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?July 8, 2023 | proactiveinvestors.comNanoViricides says clinical trial progressing satisfactorily...NanoViricides says clinical trial progressing satisfactorily for...July 6, 2023 | finance.yahoo.comClinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical NeedsJune 29, 2023 | finance.yahoo.comNanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2June 29, 2023 | proactiveinvestors.comNanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2June 29, 2023 | finanznachrichten.deNanoViricides, Inc.: NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have BegunJune 29, 2023 | finance.yahoo.comNanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have BegunMay 31, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ETMay 19, 2023 | proactiveinvestors.comBig box retailers lead mixed earnings week as consumers shift focus from goods to experiencesMay 16, 2023 | proactiveinvestors.comNanoViricides ends fiscal 3Q with strong cash runway to begin clinical trials of broad-spectrum COVID drugMay 16, 2023 | finanznachrichten.deNanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to BeginMay 16, 2023 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to BeginMay 4, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York CityApril 25, 2023 | finance.yahoo.comNanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug IngredientSee More Headlines Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Company Calendar Last Earnings11/15/2021Today9/27/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.25 High Stock Price Forecast$5.25 Low Stock Price Forecast$5.25 Forecasted Upside/Downside+269.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,110,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.87% Return on Assets-32.19% Debt Debt-to-Equity RatioN/A Current Ratio28.46 Quick Ratio28.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.71Miscellaneous Outstanding Shares11,640,000Free Float11,123,000Market Cap$16.53 million OptionableOptionable Beta1.17 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Anil R. Diwan Ph.D. (Age 64)Exec. Chairman, Pres, CEO & Sec. Comp: $400kMs. Meeta R. Vyas B.S. (Age 64)M.B.A., SB, MBA, Chief Financial Officer Comp: $129.6kDr. Randall W. Barton Ph.D. (Age 76)Chief Scientific Officer & Chief Regulatory Officer Key CompetitorsCalciMedicaNASDAQ:CALCVBI VaccinesNASDAQ:VBIVNightHawk BiosciencesNYSE:NHWKRenovoRxNASDAQ:RNXTTonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 2,600 shares on 8/15/2023Ownership: 0.000%Two Sigma Securities LLCBought 24,131 shares on 8/14/2023Ownership: 0.207%Renaissance Technologies LLCBought 7,506 shares on 8/11/2023Ownership: 0.675%View All Institutional Transactions NNVC Stock - Frequently Asked Questions Should I buy or sell NanoViricides stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NNVC shares. View NNVC analyst ratings or view top-rated stocks. What is NanoViricides' stock price forecast for 2023? 1 Wall Street analysts have issued 12-month target prices for NanoViricides' shares. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they anticipate the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 269.7% from the stock's current price. View analysts price targets for NNVC or view top-rated stocks among Wall Street analysts. How have NNVC shares performed in 2023? NanoViricides' stock was trading at $1.11 on January 1st, 2023. Since then, NNVC shares have increased by 27.9% and is now trading at $1.42. View the best growth stocks for 2023 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.03. When did NanoViricides' stock split? NanoViricides shares reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is NanoViricides' stock symbol? NanoViricides trades on the New York Stock Exchange (NYSE) under the ticker symbol "NNVC." Who are NanoViricides' major shareholders? NanoViricides' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.68%), Two Sigma Securities LLC (0.21%) and Citadel Advisors LLC (0.00%). View institutional ownership trends. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NanoViricides' stock price today? One share of NNVC stock can currently be purchased for approximately $1.42. How much money does NanoViricides make? NanoViricides (NYSE:NNVC) has a market capitalization of $16.53 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. How can I contact NanoViricides? NanoViricides' mailing address is 1 Controls Drive, Shelton CT, 06484. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at clyburn@tradigitalir.com, or via fax at 203-859-5095. This page (NYSE:NNVC) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.